This brand name is authorized in Israel
The drug QULIPTA contains one active pharmaceutical ingredient (API):
|
1
Atogepant
UNII 7CRV8RR151 - ATOGEPANT
|
|
Atogepant is indicated for prophylaxis of migraine. Atogepant shows affinity to several receptors of the calcitonin/CGRP-receptor family. In view of the clinically relevant free plasma concentrations of atogepant and the fact that CGRP and amylin-1 receptors are considered to be involved in the pathophysiology of migraine, inhibitory effects of atogepant at these receptors could be of clinical relevance. However, the precise mechanism of action of atogepant in the prophylaxis of migraine remains to be established. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02CD07 | N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CD Calcitonin gene-related peptide (CGRP) antagonists | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 9282, 9283, 9284 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
